Detalhe da pesquisa
1.
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
PLoS One
; 7(8): e41936, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-22870265
2.
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
PLoS One
; 5(9): e12873, 2010 Sep 21.
Artigo
Inglês
| MEDLINE | ID: mdl-20877623
3.
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
AIDS Res Hum Retroviruses
; 25(11): 1107-16, 2009 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-19943789
4.
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
J Virol
; 80(10): 4717-28, 2006 May.
Artigo
Inglês
| MEDLINE | ID: mdl-16641265